Stockreport

Maze Therapeutics: An Innovative, Nature-Driven Platform [Seeking Alpha]

Maze Therapeutics, Inc.  (MAZE) 
PDF MZE829 targets APOL1-mediated kidney disease with a dual inhibition strategy, potentially surpassing Vertex's first-mover approach; Phase 2 HORIZON data is expected in [Read more]